HLX37 injection, a subsidiary of Fosun Pharmaceuticals (600196.SH) Holdings, was approved for clinical trials

Zhitongcaijing · 12/01/2025 09:17

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (collectively known as “Fuhong Hanlin”) received approval from the State Drug Administration to conduct clinical trials for HLX37 injections (that is, recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injections; “HLX37” for short) to treat patients with advanced/metastatic solid tumors. Fu Hong Hanlin plans to conduct phase I clinical trials of HLX37 in China when conditions are met.

HLX37 is a recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody independently developed by the Group. It is intended for the treatment of advanced/metastatic solid tumors. Pre-clinical studies to date have shown that HLX37 can inhibit tumor growth and has good safety.